Bennell, Kim L.
,
Keating, Catherine
Lawford, Belinda J.
Kimp, Alexander J.
Egerton, Thorlene
Brown, Courtney
Kasza, Jessica
Spiers, Libby
Proietto, Joseph
Sumithran, Priya
Quicke, Jonathan G.
Hinman, Rana S.
Harris, Anthony
Briggs, Andrew M.
Page, Carolyn
Choong, Peter F.
Dowsey, Michelle M.
Keefe, Francis
Rini, Christine
Funding for this research was provided by:
Medibank Private
National Health and Medical Research Council (APP1079078)
Article History
Received: 27 June 2019
Accepted: 26 February 2020
First Online: 12 March 2020
Ethics approval and consent to participate
: Ethical approval has been obtained from the University of Melbourne Human Research Ethics Committee (HREC No. 1750443). All participants will provide written informed consent.
: Not applicable.
: JP was Chair of the Medical advisory Board for Liraglutide 3 mg (Saxenda) for Novo Nordisk Australia and Has given lectures on the management of obesity for I Nova marketers of Duromine (Phentermine) and Contrave (Bupropion and Naltrexone).